MDX 11

Drug Profile

MDX 11

Alternative Names: Anti-AML/SCCL-trigger monoclonal antibody; Anti-CD15 monoclonal antibody PM-81; Monoclonal antibody PM-81

Latest Information Update: 20 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 20 Aug 2002 Discontinued - Phase-II for Acute myeloid leukaemia in USA (unspecified route)
  • 20 Oct 1997 Phase-II clinical trials for Acute myeloid leukaemia in USA (Unknown route)
  • 01 Oct 1996 A study has been added to the therapeutic trials, adverse effects, immunogenicity and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top